Rather, CD19-expressing B-ALL cells are continuously being deleted under this pressure, until leukaemia either downregulates CD19 (in two of our samples) or reprograms via downregulation of PAX5 and EBF1 to drive a CD19 CAR-resistant relapse. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.